US prevalence
38M US adults / 11.6% population
Source: CDC 2024
Affiliate-supportedIndependent editorialWe never sell medicationSee how
A chronic condition affecting how the body processes blood sugar (glucose).
Type 2 diabetes is a chronic metabolic disease characterized by insulin resistance + relative insulin deficiency, leading to elevated blood glucose. Approximately 38 million US adults have T2D (11.6% of population), with another 98 million having prediabetes. GLP-1 receptor agonists (Ozempic, Mounjaro, Rybelsus, Trulicity) are first- or second-line therapies that improve glycemic control while typically reducing weight and (for some) reducing cardiovascular event risk.
US prevalence
38M US adults / 11.6% population
Source: CDC 2024
Annual US burden
$413 billion
Annual US direct + indirect cost
Source: ADA 2022
GLP-1 role
First- or second-line therapy per ADA Standards of Care; preferred over older sulfonylureas due to lower hypoglycemia risk + cardiovascular benefits.
GLP-1 agonists enhance glucose-dependent insulin secretion and suppress glucagon, lowering blood sugar without high hypoglycemia risk. Recent CVOT trials (LEADER, SUSTAIN-6, REWIND, SURPASS-CVOT) show cardiovascular benefits in T2D patients with established heart disease.
Diagnosis requires one of: A1c ≥ 6.5%, fasting plasma glucose ≥ 126 mg/dL, 2-hour oral glucose tolerance test ≥ 200 mg/dL, or random glucose ≥ 200 mg/dL with classic symptoms. Diagnosis should be confirmed with repeat testing unless symptoms are obvious. A1c reflects 3-month average glucose; ideal target is generally < 7% for most adults.
Cheap, well-tolerated, reduces glucose production by liver. A1c reduction: 1–2%. Used in 80% of T2D patients.
Ozempic, Trulicity, Mounjaro, Rybelsus. A1c reduction: 1–2% + weight loss + CVD risk reduction. Now ADA-recommended for T2D with established CVD or high CVD risk.
Jardiance, Farxiga, Invokana. Cause kidney to excrete excess glucose in urine. Cardiovascular and renal benefits.
Used when other meds insufficient, or in newly-diagnosed patients with very high A1c (>10%). Long-acting (basal) + rapid-acting (mealtime).
Make an appointment if you have:
Not sure which medication is right for you?
Take our 60-second quiz and get a personalized match.
Take the quizEducational content; not a substitute for professional medical advice. Always consult a licensed clinician.
Diagnostic algorithm
Who diagnoses: Primary care provider, endocrinologist. This is the standard clinical algorithm — not self-diagnosis guidance. Always work with your clinician for actual diagnosis.
Fasting plasma glucose OR HbA1c blood draw
Threshold: A1C 5.7-6.4% = prediabetes; ≥6.5% = diabetes
Repeat A1C or fasting glucose on separate day to confirm
Threshold: Two abnormal results required for diagnosis
When A1C and FPG are conflicting or borderline
Threshold: 2-hour OGTT ≥200 mg/dL = diabetes
Lipid panel, kidney function (eGFR + ACR), liver enzymes, retinal exam baseline
Threshold: Establishes comorbidity baseline
Lifestyle counseling + metformin (typically first-line) ± GLP-1 if obese or CVD risk
Source: ADA Standards of Care in Diabetes (annual update)
Treatment decision criteria
Criteria prescribers commonly weigh. Treatment decisions are your prescriber's — these are the factors that inform that decision.
Each row links to its full review with current pricing, FDA status, and the best telehealth providers offering it. Discuss with your prescriber — these are treatment options, not personal recommendations.
| Drug | Avg monthly cost | Indication match | Notes | Best providers |
|---|---|---|---|---|
| Ozempic semaglutide | $968–$1100/mo | 98/100 | FDA-approved for type 2 diabetes + cardiovascular risk reduction | Compare |
| Mounjaro tirzepatide | $1023–$1330/mo | 96/100 | FDA-approved for type 2 diabetes — strongest A1c reduction in head-to-head trials | Compare |
| Trulicity dulaglutide | $987/mo | 92/100 | FDA-approved for type 2 diabetes + cardiovascular risk reduction | Compare |
| Rybelsus semaglutide | $850–$1100/mo | 90/100 | FDA-approved for type 2 diabetes — oral semaglutide | Compare |
| Victoza liraglutide | $1023/mo | 85/100 | FDA-approved for type 2 diabetes + cardiovascular risk reduction | Compare |
| Bydureon BCise exenatide ER | $870/mo | 78/100 | FDA-approved for type 2 diabetes — weekly extended-release exenatide | Compare |
| Byetta exenatide | $830/mo | 70/100 | FDA-approved for type 2 diabetes — twice-daily exenatide | Compare |
Educational only. Discuss with your prescriber — these are treatment options, not personal recommendations. Indication-match scores reflect FDA approval status and published clinical evidence, not individual patient suitability.